Fig 5 - by Harshita Sharma (4836180)

Effect of point mutation on the protein structure and change in free energy. by Mohd Hassan Baig (441304)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

Downregulation of CIP2A leads to decrease of phosphorylated Akt in lung cancer cells. by Liang Ma (37793)

SH-SY5Y cells are responsive to acute insulin stimulation and altered insulin signaling impacts choline uptake by CHT. by Katherine J. Fishwick (768451)

Temperature-Responsive Peptide–Nucleotide Coacervates by Tiemei Lu (4244926)

“…Partitioning of two dyes proves that the local hydrophobicity inside the peptide–nucleotide coacervates is different for every nucleoside triphosphate. We derive a simple relation between the temperature and salt concentration at the critical point based on a mean-field model of phase separation. …”

Temperature-Responsive Peptide–Nucleotide Coacervates by Tiemei Lu (4244926)

“…Partitioning of two dyes proves that the local hydrophobicity inside the peptide–nucleotide coacervates is different for every nucleoside triphosphate. We derive a simple relation between the temperature and salt concentration at the critical point based on a mean-field model of phase separation. …”

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Schematic diagram of soil sampling (a: Layout of sample points; b: Sampling of soil profile). by Zhanhong Li (5448866)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

Overtrained mice show dichotomous modulation of timing-dependent synaptic depression (tLTD) in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects: